L

Latent Labs

Develops foundational AI for molecular biology

Forward Deployed AI Engineer

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's, Master's, PhD
London, UK
HybridHybrid in London; on-site work at international partner locations as needed.
Solution EngineeringImplementation & Technical Account Management

About the job

Requirements
  • A degree (BSc, MSc, or PhD) in Computer Science, Machine Learning, or a closely related quantitative field.
  • A strong grounding in software engineering principles and modern machine learning frameworks.
  • Significant experience designing, deploying, and maintaining infrastructure for large-scale model serving, with hands-on experience building robust API layers around machine learning models.
  • Direct experience deploying AI systems for external customers, with the ability to explain complex technical concepts to non-technical stakeholders.
  • Hands-on experience with AWS; experience with other major cloud platforms such as GCP or Azure is also noted.
  • Comfort with containerisation using Docker and Kubernetes, CI/CD pipelines, and cloud-native architectures.
  • Ability to work across functions, lead technical discussions, write clear documentation, and present solutions to senior stakeholders.
  • Adaptability in a dynamic environment involving shifting priorities and multiple customer engagements.
Responsibilities
  • Drive the end-to-end technical deployment of Latent Labs models into customer environments and integrate them with existing scientific and IT infrastructure.
  • Design and build production-grade API integrations, data pipelines, and model-serving infrastructure tailored to customer requirements.
  • Work on-site or embedded with pharmaceutical and biotech partners to scope technical requirements, troubleshoot issues, and deliver solutions.
  • Ensure deployments meet enterprise standards for security, performance, and reliability.
  • Serve as the technical point of contact for assigned customers and build relationships with their scientific and engineering teams, including working on-site at international partner locations as needed.
  • Gather and synthesise customer feedback into actionable insights for product, research, and platform teams.
  • Collaborate with internal teams to shape the product roadmap based on deployment learnings.
  • Create technical documentation, integration guides, and best-practice resources for customers.
  • Stay current with developments in machine-learning infrastructure, model serving, and cloud-native tooling.
  • Develop a working understanding of protein and cell biology as it relates to the product.
  • Participate in knowledge sharing, including organising and presenting at the internal reading group.
Desired Qualifications
  • Experience with biological or protein-design models, including machine-learning projects in computational biology, protein design, or related life-science domains, and understanding of biological modelling data challenges and evaluation paradigms.
  • A track record of novel contributions to generative modelling through publications, open-source work, or product features.
  • Experience delivering enterprise-grade software for security, compliance, auditability, and uptime, and understanding the distinction between prototypes and production systems.
  • Pharmaceutical or biotech industry experience, including familiarity with regulatory landscapes, data governance requirements, and scientific workflows.

About the company

Latent Labs builds foundational biology models that power generative AI for biology. It offers AI tools to help researchers design new antibodies, optimize existing enzymes, and advance genetic engineering. The models translate biological data into actionable designs and optimization suggestions for lab use, provided through collaboration with partners. The goal is to accelerate molecular biology by giving researchers AI-guided design and directions for experiments.

Company Size

11-50

Company Stage

Series A

Total Funding

$59.1M

Headquarters

London, United Kingdom

Founded

2023

Get referred to Latent Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • GenScript validated Latent-X2 in January 2026, strengthening wet-lab trust and adoption.
  • Latent-Y showed confirmed nanobody binders on six of nine targets, with single-digit nanomolar affinity.
  • AWS and NVIDIA partnerships in 2026 expand compute, distribution, and enterprise reach.

What critics are saying

  • Latent Labs had only about 20 employees in March 2026, limiting execution capacity.
  • Free access launched July 15, 2026, risking weak monetization before competitors copy features.
  • Existential risk: failed partner conversions after GenScript validation would collapse biotech credibility.

What makes Latent Labs unique

  • March 2026 Latent-Y autonomously designs antibodies from prompts, not manual workflows.
  • Latent-X2 plus Latent-Y integrates epitope selection, candidate generation, and validation end-to-end.
  • NVIDIA Blackwell and Nebius delivered over 4x training speedups and 60% faster inference.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Parental Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

36%

2 year growth

52%
Business Wire
Mar 23rd, 2026
Latent-Y AI agent designs therapeutic antibodies in hours, 56x faster than expert teams

Latent Labs has launched Latent-Y, an AI agent that autonomously designs therapeutic antibodies from text prompts, reducing weeks of expert work to hours. The system is powered by Latent-X2, the company's frontier model for drug-like antibody and peptide design. Latent-Y operates independently, analysing target molecules, identifying viable epitopes, designing antibody candidates and validating them computationally. Scientists can run the agent fully autonomously or pause at each stage for review. The London and San Francisco-based company has demonstrated lab-validated results across three antibody design campaigns, including epitope discovery yielding nanomolar-affinity binders. User studies showed PhD-level experts completed design campaigns 56 times faster using Latent-Y compared to independent expert estimates. The platform is now available to selected partners through the Latent Labs platform.

PR Newswire
Jan 28th, 2026
GenScript partners with Latent Labs as wet-lab validator for AI drug discovery model Latent-X2

GenScript Biotech Corporation has announced its role as wet-lab partner for Latent Labs' Latent-X2, a next-generation AI model that designs antibodies and peptides with drug-like properties. GenScript provides high-throughput expression, purification and functional testing of AI-generated molecules, enabling rapid iteration between computational predictions and biological performance. Using its TurboCHO™ High Throughput Platform and cell-free expression systems, GenScript screens AI-designed antibodies, minibinders and peptides to compare candidates and collect data on developability and binding. This reduces reliance on iterative wet-lab optimisation. The collaboration addresses a key industry challenge by accelerating timelines whilst improving likelihood of clinical success. Founded in 2002, GenScript supports over 200,000 customers across 100-plus countries with a team of 5,500-plus employees.

Wow Partners, Inc.
Feb 13th, 2025
Latent Labs raises $50M for AI biology

Latent Labs, an AI-based biology platform developer, has emerged from stealth mode, securing $50 million in funding. The round was co-led by Radical Ventures and Sofinnova Partners, with participation from Flying Fish, Isomer, 8VC, Kindred Capital, and Pillar VC. Notable angel investors include Jeff Dean, Aidan Gomez, and Mati Staniszewski. Founded by Simon Kohl, a key figure in the Nobel Prize-winning AlphaFold2 project, Latent Labs aims to revolutionize drug development with generative AI technology.

TechCrunch
Feb 13th, 2025
Founded by DeepMind alumnus, Latent Labs launches with $50M to make biology programmable | TechCrunch

A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.

Business Insider
Aug 8th, 2023
DeepMind's secret mafia: Meet the stealth startups emerging from Google's AI lab

Alphabet's AI research lab DeepMind nurtures the industry's top talent. It's also spawned a wave of secretive new startups.